USFDA completes inspections at Suven Pharmaceuticals’ API, Formulations facilities

23 Feb 2024 Evaluate

US Food & Drug Administration (US FDA) has completed Pre-Approval Inspections (PAI) and Good Manufacturing Practices (GMP) inspections at Suven Pharmaceuticals’ Active Pharmaceutical Ingredients (API) and Formulations facilities (Unit-3 and Unit-5, respectively) in Pashamylaram, Hyderabad, India. The inspections were conducted from February 12, 2024, to February 23, 2024. No Form 483 has been issued as a result of the inspection.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.


Suven Pharma Share Price

625.00 9.20 (1.49%)
12-Apr-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1539.65
Dr. Reddys Lab 6084.45
Cipla 1396.40
Zydus Lifesciences 961.35
Lupin 1623.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.